NEWS TODAY
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Coya Therapeutics (NASDAQ: COYA) has filed for intellectual property protectionfor the combination of COYA 301 (low-dose interleukin-2) and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs).
This combination aims to enhance regulatory T cell function and may offer a multi-pathway targeted approach for treating inflammatory diseases, including neurodegenerative, autoimmune, and metabolic conditions.
The company believes this proprietary combination could lead to value-creating business development partnerships and expand the GLP-1 market beyond diabetes and obesity.
Data suggests the combination may have additive and/or synergistic anti-inflammatory effects on multiple cell types. Coya is investigating these combinations to potentially bring forward an optimized novel therapeutic approach for several diseases.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1260Followers
76Following
8856Visitors
Follow